In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance

Journal of Clinical Microbiology

Volumn 40, Issue 6, 2002, Pages 2228-2230

  Bachmann, Stefano P ^a   Patterson, Thomas F ^a   López Ribot, José L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; CASPOFUNGIN; FLUCONAZOLE; PYRROLE DERIVATIVE;

ARTICLE; CANDIDA ALBICANS; CDR GENE; CELL WALL; DRUG MECHANISM; ERG11 GENE; FUNGAL GENE; FUNGUS ISOLATION; MDR GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC;

CANDIDA; CANDIDA ALBICANS; FUNGI;

EID: 0036266003     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.6.2228-2230.2002     Document Type: Article

References (12)

1. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species
2. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
3. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
4. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis
5. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: Influence of assay conditions
6. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar
7. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients
8. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
9. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
10. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
11. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance